[Perioperative immune modulation in renal cell carcinoma--review of the current situation].
Surgery and immunotherapy are the mainstay in the treatment of renal cell carcinoma. Surgery, however, is associated with considerable perioperative immunodysfunction. This immunodysfunction can be modulated by pretreatment with Interleukin-2 (IL-2), which appears to prolong tumour-specific survival. Perioperative immunomodulation could help close the therapeutic gap between neoadjuvant and adjuvant immunotherapy. This article reviews recent literature and presents original data of 63 patients.
Böhm
M
M
Urologische Klinik, Otto-von-Guericke Universität, Leipziger Str. 44, 39120 Magdeburg. malte.boehm@medizin.uni-magdeburg.de
Klatte
T
T
Allhoff
E P
EP
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000601:surgery*; D020360:Neoadjuvant Therapy; D015996:Survival Rate
D000970:Antineoplastic Agents; D007376:Interleukin-2